Updated post hoc analysis of a randomised trial in high-risk hepatocellular carcinoma after resection or ablation: adjuvant atezolizumab plus bevacizumab vs active surveillance no longer improved recurrence-free survival (HR 0.90, 95% CI 0.72-1.12).
Secondary analysis
Yopp et al. Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma